Loading clinical trials...

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | Clinical Trials | Clareo Health

COMPLETEDPHASE1

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies

NCT03884556•Trishula Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Advanced solid tumor malignancy or relapsed/refractory lymphoma, or
•* eligible to receive single-agent pembrolizumab as standard of care, or
•* eligible to receive single-agent docetaxel as standard of care, or
•* advanced pancreatic adenocarcinoma and eligible to receive gemcitabine plus nab-paclitaxel as standard of care.
•2. Age 18 years or older, is willing and able to provide informed consent
•3. Evidence of measurable disease
•4. Life expectancy \> 12 weeks and Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

Exclusion Criteria

•1. History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
•2. Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
•3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
•4. History of severe autoimmune disease
•5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

Locations (16)

UC Irvine Cancer Center

Orange, California, United States

UC Davis Comprehensive Cancer Center

Sacramento, California, United States

University of California, San Francisco

San Francisco, California, United States

Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Norton Cancer Institute

Louisville, Kentucky, United States

Nebraska Cancer Center Oncology Hematology West P.C.

Omaha, Nebraska, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Columbia University Irving Medical Center

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Montefiore Medical Center

The Bronx, New York, United States

Key Dates

Start Date

April 10, 2019

Primary Completion Date

November 30, 2022

Completion Date

September 29, 2023

Last Updated

July 2, 2025

Enrollment

ACTUAL participants

Conditions

Solid TumorLymphoma

Interventions

TTX-030

DRUG

Pembrolizumab

DRUG

Gemcitabine

DRUG

nab paclitaxel

DRUG

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

NCT06263491

Mantle Cell Lymphoma

View study

RECRUITINGPHASE3

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

NCT06337318

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

A Study of PYX-201 in Advanced Solid Tumors

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.